Interim [¹⁸F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.

ABSTRACT:

Purpose

In an attempt to identify biomarkers that can reliably predict long-term outcomes to immunotherapy in metastatic melanoma, we investigated the prognostic role of [¹⁸F]FDG PET/CT, performed at baseline and early during the course of anti-PD-1 treatment.

Methods

Twenty-five patients with stage IV melanoma, scheduled for treatment with PD-1 inhibitors, were enrolled in the study (pembrolizumab, n = 8 patients; nivolumab, n = 4 patients; nivolumab/ipilimumab, 13 patients). [¹⁸F]FDG PET/CT was performed before the start of treatment (baseline PET/CT) and after the initial two cycles of PD-1 blockade administration (interim PET/CT). Seventeen patients underwent also a third PET/CT scan after administration of four cycles of treatment. Evaluation of pa

SUBMITTER: Sachpekidis C 

PROVIDER: S-EPMC8113306 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature